Humaid Al-Shamsi, Chairman of Nexomic, Chief Executive Officer of Burjeel Cancer Institute (BCI), Honorary Professor at Gulf Medical University, Visiting Professor at Harvard Medical School, and Visiting Scientist at Dana-Farber Cancer Institute, shared on LinkedIn:
“Nexomic is pleased to announce Prof. Salah-Eddin Al-Batran, as a member of its Advisory Board.
Prof. Al-Batran is the world expert in Gastroesophageal cancer and the Director/Founder of The Frankfurt Institute of Clinical Cancer Research IKF GmbH ,Germany.
He is the Founder and Chair of the German (FLOT-AIO) Gastric Cancer Group, which coordinated a network of more than 500 medical centers located in Germany and the European Union.
His internationally recognised leadership in gastrointestinal oncology, molecular profiling and practice-changing clinical trials, particularly in gastroesophageal cancers, will strengthen Nexomic’s work in precision oncology and help translate multi-omic AI insights into biomarker-guided therapeutic strategies in gastroesophageal cancers and solid tumors.”
You can also read: Virtual Webinar on Gastric and Gastroesophageal Cancers – IC-OS
